New drugs may improve, complicate treatment for multiple sclerosis

Nature Medicine

Volumn 16, Issue 3, 2010, Pages 272-

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; CLADRIBINE; FINGOLIMOD; GLATIRAMER; NATALIZUMAB; PLACEBO;

BRAIN HEMORRHAGE; CARDIOVASCULAR DISEASE; DNA STRAND BREAKAGE; DRUG DOSE COMPARISON; DRUG MEGADOSE; ENCEPHALITIS; ERYTHROCYTE COUNT; HUMAN; INFECTION; LEUKOENCEPHALOPATHY; LOW DRUG DOSE; MULTIPLE SCLEROSIS; NEOPLASM; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RELAPSE; RETINA MACULA EDEMA; SHORT SURVEY; SIDE EFFECT; VIRUS REACTIVATION;

CLADRIBINE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MULTIPLE SCLEROSIS; PROPYLENE GLYCOLS; SPHINGOSINE;

EID: 77749239727     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm0310-272     Document Type: Short Survey

References (3)

1. Kappos, L. et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N. Engl. J. Med. 362, 387-401 (2010)
2. Cohen, J.A. et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N. Engl. J. Med. 362, 402-415 (2010)
3. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N. Engl. J. Med. 362, 416-426 (2010)